Capricor Therapeutics Inc (NASDAQ:CAPR) 2018 Q1 Sentiment Change, Now at 0.44

June 26, 2018 - By Gregory Tomko

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Corporate Logo

Positions for Capricor Therapeutics Inc (NASDAQ:CAPR)

“Big money sentiment for Capricor Therapeutics Inc (NASDAQ:CAPR) in Q1 2018 decreased to 0.44, according to Securities and Exchange Commission filings. That’s down -3.89, from 2017Q4’s 4.33. 4 hedge funds opened new and increased equity positions, while 9 decreased and sold their equity positions in Capricor Therapeutics Inc so the sentiment has dropped. These funds own 1.04 million shares, that’s down from 4.44 million shares in 2017Q4. Funds holding Capricor Therapeutics Inc in top 10 changed to 0 from 0 for the same number . 4 Investors Sold All; 5 Reduced Holdings; 1 increased stakes while 3 hedge funds bought stakes.

Most Capricor Therapeutics Inc Shareholders

Apriem Advisors owns 50,000 shares in Capricor Therapeutics Inc as of Q1 2018. Capricor Therapeutics Inc’s shareholder Acadian Asset Management Llc owns 60,753 shares as of Q1 2018. Furthermore, Bank Of America Corp De reported 5,500 shares in Capricor Therapeutics Inc equivalent to 0% of its US long stock exposure. The New York-based fund Bank Of New York Mellon Corp have invested about 0% of the institutional investor’s stock portfolio in Capricor Therapeutics Inc. The New York-based fund Blackrock Inc. holds 4,119 shares or 0% of their US long stock exposure.

Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel therapeutics primarily for the treatment of cardiovascular diseases.The firm is worth $40.67 million. The companyÂ’s development stage drug candidates for cardiovascular diseases include CAP-1002 that is in Phase II clinical trials; and CAP-2003, which is in pre-clinical development for the treatment of certain cardiac and inflammatory conditions.16.44 is the P/E ratio.

CAPR reached $1.397 during the last trading session after $0.003 change.Capricor Therapeutics, Inc. has volume of 58,179 shares. Since June 26, 2017 CAPR has risen 61.45% and is uptrending. CAPR outperformed the S&P500 by 48.88%.

Earnings report for Capricor Therapeutics, Inc. (NASDAQ:CAPR) is anticipated on August, 9., as reported by Faxor. Analysts forecast 18.75 % diference or $-0.13 from the $-0.16 EPS from 2017. -7.14 % EPS growth is what Wall Street’s sees after $-0.14 reported EPS last quarter.

Deutsche Bank & Trust Ag stated it has 600 shs. Geode Capital Mngmt Ltd Liability has invested 0% in Capricor Therapeutics, Inc. (NASDAQ:CAPR). Acadian Asset Mgmt Lc holds 60,753 shs or 0% of its capital. Virtu Fincl Limited Liability Company holds 0% or 52,410 shs in its capital. Commercial Bank Of America De stated it has 0% of its capital in Capricor Therapeutics, Inc. (NASDAQ:CAPR). The New York-based Perceptive Advsrs Limited Liability Corp has invested 0% in Capricor Therapeutics, Inc. (NASDAQ:CAPR). Morgan Stanley invested in 2 shs. Royal Natl Bank Of Canada holds 0% or 232 shs. Vanguard Grp Incorporated holds 0% or 712,533 shs. 50,000 were accumulated by Apriem. Blackrock Incorporated has invested 0% in Capricor Therapeutics, Inc. (NASDAQ:CAPR). Northern Corp invested 0% in Capricor Therapeutics, Inc. (NASDAQ:CAPR). Cordasco Financial Networks holds 0% or 3,100 shs in its capital. Architects reported 2,000 shs stake. Bancshares Of Mellon Corp holds 0% in Capricor Therapeutics, Inc. (NASDAQ:CAPR) or 26,762 shs.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Ratings Coverage

In total 2 analysts cover Capricor Therapeutics (NASDAQ:CAPR). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. (NASDAQ:CAPR) has 100% bullish analysts. 4 are the (NASDAQ:CAPR)’s ratings reports on 26 Jun 2018 according to StockzIntelligence Inc. On Thursday, March 29 H.C. Wainwright maintained the shares of CAPR in report with “Buy” rating. On Friday, January 26 the stock of Capricor Therapeutics, Inc. (NASDAQ:CAPR) has “Buy” rating given by H.C. Wainwright. On Friday, May 11 the firm earned “Buy” rating by H.C. Wainwright.

Another two news for Capricor Therapeutics, Inc. (NASDAQ:CAPR) were recently released by: Globenewswire.com on June 13, 2018 with title “Detailed Research: Economic Perspectives on CarGurus, ArcelorMittal, Capricor Therapeutics, B&G Foods, Ionis …”. The other Nasdaq.com‘s article was titled “Capricor Therapeutics to Present at the 2018 BIO International Convention in Boston” and released on May 29, 2018.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.